BioSpace News Archive

Only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting

BioArctic AB announced that the company’s partner Eisai will conduct four oral presentations related to the drug candidate BAN2401 at the 13th Clinical Trials on Alzheimer’s Disease Conference on November 4-7.

TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced financial results for the third quarter ending September 30, 2020, and provided a business update.

The Chief Executive Officer for BetterLife Pharma Inc., an emerging biotechnology company currently preparing for clinical trials of AP-003, its interferon alpha 2b COVID-19 treatment, joined investor portal Proactive to discuss the key differences between the interferon inhalation formula used by BetterLife against that used successfully by Synairgen PLC.

Biodesix, Inc. announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share.

Employees have not been getting the kind of support they need from their employers to better manage their emotional and physical health during the pandemic, according to the results of a new report from WebMD Health Services, a subsidiary of WebMD Health Corp.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that the Company’s Board of Directors has approved a fourth-quarter 2020 dividend of $0.17 per share, a 6.25% increase over the $0.16 per share declared for each of the four preceding quarters.

Dr. Reddy’s Laboratories Ltd. announced that Parag Agarwal will be joining the Company as Chief Financial Officer on November 2, 2020.

Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab 700 mg, an investigational neutralizing antibody, for $375 million.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the first patient has been dosed in the Phase 1/2 ASPEN-02 study evaluating the combination of ALX148, a next-generation CD47 blocker, with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome.